Artificial intelligence is revolutionizing drug discovery, potentially slashing the decade-long timeline and billion-dollar costs associated with bringing new medicines to market. In this interview, Christian Olsen, VP of Biologics at Dotmatics, discusses how AI is reshaping pharmaceutical R&D by accelerating drug target identification and high-throughput screening. By leveraging vast datasets and automation, AI enables scientists to uncover new treatment strategies and revisit overlooked therapeutic opportunities.
Discover how AI is driving breakthroughs in cancer, diabetes, cardiovascular disease, and neurology, and how Dotmatics is empowering pharma and biotech companies to develop life-saving treatments faster than ever.
Learn More About Dotmatics
Schedule a meeting with our product experts today for a personalized demo of Luma's AI capabilities.